FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of cardiovascular diseases. Disclosed is the use of a pharmaceutical composition containing ethyl ester of eicosapentaenoic acid to reduce the risk of myocardial infarction and/or stroke in a subject receiving statin therapy, where the individual has an initial fasting triglyceride level of 135 mg/dL to 500 mg/dl and wherein 4 g of ethyl ester of eicosapentaenoic acid is administered to a subject a day for a period of at least 4 months. Also disclosed is use of a pharmaceutical composition containing ethyl ester of eicosapentaenoic acid to reduce the risk of myocardial infarction and/or stroke in a subject, receiving statin therapy with established cardiovascular disease.
EFFECT: group of inventions provides reducing a risk of myocardial infarction and/or stroke in a subject.
17 cl, 4 dwg, 1 ex
